NCT00831311View on ClinicalTrials.gov

Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants

PHASE2CompletedINTERVENTIONAL
Enrollment

624

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

November 30, 2005

Study Completion Date

March 31, 2007

Conditions
DiphtheriaTetanusPertussisHaemophilus Influenzae Type bPoliomyelitis
Interventions
BIOLOGICAL

DTaP-IPV-HB-PRP~T

0.5 mL, Intramuscular

BIOLOGICAL

DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine

0.5 mL, Intramuscular (right and left thighs, respectively)

Trial Locations (1)

Unknown

Córdoba

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00831311 - Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinean Infants | Biotech Hunter | Biotech Hunter